Swedish-based biopharmaceutical company Hansa Medical plans to acquire the rights to cancer immunotherapy using antibody modulating enzymes, through the acquisition of glycobiology therapeutic antibodies developer Immago Biosystems Ltd.

Immago Biosystems is a spinout company of the University of Oxford .

Specialist pharmaceutical company Knight Therapeutics has acquired an additional 15.8% stake in Canadian-based pharmaceutical company Pediapharm, to become an 18.5% stakeholder of the company.

Upon completion of the transaction, Knight Therapeutics will hold 757,500 warrants that are convertible into common shares of Pediapharm at any time until March 2019.